El retatroptida, un agonista triple de Eli Lilly, mejoró significativamente el peso, la hemoglobina glicosilada A1C, el dolor de la osteoartritis de rodilla y la apnea obstructiva del sueño, lo que demuestra su notable potencial en el tratamiento de la obesidad y sus complicaciones.
Indianápolis, 6 de junio de 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), fabricante de Zepbound (tezapatida) y Foundayo (ofofoglitazona), anunció hoy nuevos resultados p…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Preguntas frecuentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
